Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2022. Journal of the National Comprehensive Cancer Network : JNCCN Caudell, J. J., Gillison, M. L., Maghami, E., Spencer, S., Pfister, D. G., Adkins, D., Birkeland, A. C., Brizel, D. M., Busse, P. M., Cmelak, A. J., Colevas, A. D., Eisele, D. W., Galloway, T., Geiger, J. L., Haddad, R. I., Hicks, W. L., Hitchcock, Y. J., Jimeno, A., Leizman, D., Mell, L. K., Mittal, B. B., Pinto, H. A., Rocco, J. W., Rodriguez, C. P., Savvides, P. S., Schwartz, D., Shah, J. P., Sher, D., St John, M., Weber, R. S., Weinstein, G., Worden, F., Yang Bruce, J., Yom, S. S., Zhen, W., Burns, J. L., Darlow, S. D. 2022; 20 (3): 224-234

Abstract

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.

View details for DOI 10.6004/jnccn.2022.0016

View details for PubMedID 35276673